english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Prescrire's ratings of new products and indications over the past 10 years

Tripoliponumab: French firm Neuronodev demands withdrawal of marketing authorisation and approves 150 million euros for patients

• Decline in vigilance: beware of collateral damage(s)

Ceftazidime + avibactam (Zavicefta°). An option in the case of cephalosporin resistance

In the March issue of Prescrire International: the annual Prescrire Awards for drugs, packaging and information

Hodgkin disease: two drugs that are not beneficial to patients

Hospitalised children: errors detected by parents and family members

Early syphilis: screen and treat to prevent transmission

EMA's advice to drug companies: conflicting roles

Prescrire's ratings system: new drugs and indications, at a glance

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90